Anaplastic Astrocytoma

Anaplastic astrocytoma is a cancer of the brain that grows from star-shaped support cells called astrocytes. Doctors now use the newer WHO system (2021+) and call this tumor astrocytoma, IDH-mutant, grade 3. “Grade 3” means it grows faster than low-grade tumors and needs full treatment. It spreads into nearby brain tissue, so surgery alone is not usually enough. Diagnosis today combines what the cells look like under the microscope with modern molecular tests (for example, IDH mutation, ATRX, TP53) to make sure the name and grade are correct. PMC+2PMC+2

Anaplastic astrocytoma is a fast-growing brain tumor that comes from astrocytes (support cells in the brain). In the modern WHO 2021 system, most tumors formerly called “anaplastic astrocytoma” are classified as astrocytoma, IDH-mutant (grade 3). This name matters because IDH-mutant tumors behave differently from glioblastoma (IDH-wildtype) and are treated using evidence specific to IDH-mutant disease. PMC+1

Diagnosis uses MRI, surgery or biopsy for tissue, and molecular tests (especially IDH mutation and 1p/19q status). These tests guide treatment choices such as radiotherapy and temozolomide, based largely on the CATNON trial showing a survival benefit from adjuvant (after radiation) temozolomide in 1p/19q-non-codeleted grade 3 gliomas (the group that maps to IDH-mutant astrocytoma grade 3). PMC

---

Other names

You may still see older terms in reports or on websites. Common alternate names include: anaplastic astrocytoma, grade 3 astrocytoma, high-grade astrocytoma (grade 3), and astrocytoma, IDH-mutant, CNS WHO grade 3 (the preferred modern term). The word “anaplastic” has been phased out; clinicians now say “grade 3.” Cleveland Clinic+2National Brain Tumor Society+2

---

Types

Doctors no longer split “anaplastic astrocytoma” into many subtypes by appearance alone. Instead, they classify astrocytoma, IDH-mutant into grades 2, 3, or 4 based on microscope features and certain gene changes. Grade 3 tumors show rapid cell division (mitoses) but do not have the necrosis or microvascular proliferation that define grade 4. Loss of ATRX and abnormal p53 staining support the astrocytoma pathway; 1p/19q codeletion must be absent (otherwise it is an oligodendroglioma). PMC+2Lippincott Journals+2

Causes

1. IDH1/IDH2 mutation (driver): Most grade-3 adult astrocytomas carry a change in IDH that produces an “oncometabolite” (D-2-hydroxyglutarate) and pushes cells toward tumor growth. This mutation defines the tumor type. ScienceDirect

2. TP53 pathway changes: TP53 mutations (often strong p53 staining) are common and disable a key “DNA damage brake.” PMC+1

3. ATRX loss: Loss of the ATRX protein is a hallmark of IDH-mutant astrocytoma and helps keep chromosomes unstable, aiding growth. BioMed Central

4. Not having 1p/19q codeletion: Lack of this co-deletion steers a diffuse glioma toward the astrocytoma pathway instead of oligodendroglioma. PMC

5. CDKN2A/B homozygous deletion (in some tumors): This deletion signals more aggressive behavior and upgrades IDH-mutant astrocytoma to grade 4 when present. (Its absence helps fit grade 3.) PMC

6. Prior head/neck ionizing radiation: A rare but proven external risk factor for later gliomas. Mayo Clinic+1

7. Li-Fraumeni syndrome (germline TP53): A rare inherited syndrome that raises glioma risk. SAGE Journals

8. Neurofibromatosis type 1 (NF1): An inherited condition that increases glial tumor risk. ASC Publications

9. Lynch syndrome / constitutional mismatch repair deficiency (CMMRD): Mismatch-repair defects raise risk for high-grade gliomas. PMC+1

10. Tuberous sclerosis complex (TSC): Best known for SEGA, but broadly a glioma-predisposition syndrome. ASC Publications

11. Polymerase proofreading mutations (POLE/POLD1): Rare germline defects that predispose to gliomas. Lippincott Journals

12. Older age (adult pattern): Astrocytoma, IDH-mutant grade 3 is mainly an adult tumor; risk of brain tumors rises with age. Cancer Research UK

13. Male sex (slight predominance reported in gliomas): Several series show modest male predominance in adult gliomas. PMC

14. Family history of glioma (rare): Familial clustering exists but explains a small fraction of cases. UpToDate

15. Immune and atopy history: Some studies suggest an inverse link between allergic diseases and glioma risk. Frontiers

16. Genome-wide risk variants (common SNPs): Low-penetrance variants (e.g., near TERT, RTEL1) modestly shift risk in populations. JNCCN

17. High-dose therapeutic radiation in childhood cancer survivors: Dose-related increase in later glioma risk. The Journal of Neuroscience

18. Occupational chemicals (uncertain): Evidence is mixed and not conclusive for most exposures. moffitt

19. Non-ionizing EMF from phones (not proven): Large reviews do not confirm a causal link for diffuse gliomas. UpToDate

20. Tumor evolution from lower grade IDH-mutant astrocytoma: Some grade-2 tumors transform over time to grade 3 with new mutations and faster growth. AANS

---

Common symptoms

Symptoms depend on tumor location and size. They often develop over weeks to months and may fluctuate.

1. Headache that is persistent or worse in the morning (pressure effect). AANS

2. Seizures (new “fits,” staring spells, or jerking). Mayo Clinic

3. Nausea or vomiting (raised pressure). Mayo Clinic

4. Personality or behavior change (frontal lobe involvement). American Brain Tumor Association

5. Trouble speaking or finding words (dominant temporal/frontal areas). National Brain Tumor Society

6. Weakness on one side of the body or clumsiness. AANS

7. Numbness or tingling in a limb or face. National Brain Tumor Society

8. Vision changes (blurred, double vision, or field loss). AANS

9. Balance problems or dizziness. National Brain Tumor Society

10. Memory trouble or confusion. American Brain Tumor Association

11. Extreme tiredness (fatigue). National Brain Tumor Society

12. Head pressure with coughing/straining (Valsalva worsens pressure). Mayo Clinic

13. Sleep disruption from headache or seizures. NINDS

14. Aphasia (word output or comprehension problems). Mayo Clinic

15. Papilledema-related visual symptoms (due to raised intracranial pressure). Cleveland Clinic

---

Diagnostic tests

A) Physical examination (bedside clinical checks)

1. Full neurologic exam: Checks thinking, cranial nerves, strength, sensation, balance, gait, reflexes. It helps localize where the tumor might be. NCBI

2. Cranial nerve testing: Looks for double vision, facial weakness, hearing or swallowing problems that suggest where the mass sits. Medscape

3. Motor strength and tone (MRC grading): Finds side-to-side weakness or abnormal tone from tumor pressure on motor pathways. ucsfcme.com

4. Sensory testing (light touch, pin, vibration): Maps numb areas linked to tumor location. NCBI

5. Cerebellar tests (finger–nose, heel–shin) and gait: Reveal coordination and balance problems caused by cerebellar or pathway involvement. meded.ucsd.edu

B) “Manual” bedside assessments (structured tests done by hand)

6. Mental status screening (e.g., orientation, attention, memory): Simple tasks check higher brain functions that tumors can affect. AMBOSS

7. Language assessment (naming, repetition, fluency): Quick questions and naming tests detect aphasia from dominant-hemisphere lesions. AMBOSS

8. Visual field confrontation test: A bedside check for blind spots that can result from tumors near the optic pathways. meded.ucsd.edu

9. Romberg test and tandem gait: Simple balance tests that show proprioceptive or cerebellar issues linked to tumor location. TeachMeSurgery

10. Funduscopic exam for papilledema: Looking at the optic discs can show swelling from raised brain pressure, which supports an urgent imaging workup. Medscape

C) Laboratory & pathological tests (the gold standard is tissue)

11. Stereotactic brain biopsy or surgical specimen histology: Confirms astrocytoma by microscope, shows mitoses (grade 3) and rules out necrosis/microvascular proliferation (which would be grade 4). Lippincott Journals

12. IDH1/IDH2 mutation testing (IHC/seq): Defines the tumor type (astrocytoma, IDH-mutant). IDH R132H IHC is a common first test. PMC

13. ATRX immunohistochemistry or sequencing: Loss of ATRX supports astrocytoma rather than oligodendroglioma. oncoscience.us

14. p53 immunostain / TP53 sequencing: Frequent in astrocytoma and helps support the diagnosis pathway. PMC

15. 1p/19q codeletion testing (FISH/NGS): Must be absent for astrocytoma; if present with IDH-mutation, the correct diagnosis is oligodendroglioma. Lippincott Journals

16. MGMT promoter methylation status: Not diagnostic, but provides prognostic and treatment-response information for alkylating chemotherapy. JAMA Network

D) Electrodiagnostic tests

17. EEG (electroencephalography): Records brain waves and confirms seizure tendency; useful at baseline and during treatment if seizures occur. Medscape

18. Evoked potentials (SSEPs/MEPs) for surgical planning/monitoring: Help protect motor and sensory pathways during tumor surgery. JKMS

19. Intraoperative language or motor mapping (awake mapping or DES): Real-time stimulation detects critical speech or motor areas so the surgeon can remove tumor safely. Frontiers

E) Imaging tests (essential for diagnosis, planning, and follow-up)

1. MRI brain with and without gadolinium (core test): First-line imaging for suspected glioma; shows tumor location, size, and involvement. PMC
2. Advanced MRI sequences often added:
   • Diffusion-weighted imaging (DWI/ADC): Higher cellularity in higher-grade lesions; helps grading and biopsy targeting. PMC
   • Perfusion MRI (rCBV): Higher blood volume suggests higher grade; aids treatment response vs. recurrence questions. PMC
   • MR spectroscopy: Measures tumor chemicals (e.g., choline↑, NAA↓); can support grading and sometimes reflect IDH status. PMC+1
   • Susceptibility-weighted imaging (SWI): Highlights blood products and microvasculature that may suggest higher grade. PMC
   • Functional MRI (fMRI) / DTI tractography: Maps speech and motor tracts before surgery to plan a safer resection. PMC
   • Amino-acid PET (e.g., FET, MET) or PET-MR: Improves tumor margin definition, biopsy targeting, and recurrence assessment when MRI is unclear. PMC

Non-pharmacological treatments

1. Maximal-safe neurosurgery with brain mapping
   Goal: remove as much tumor as possible without harming speech/movement. Awake or asleep mapping helps surgeons protect critical brain areas while still achieving larger resections, which is linked to better outcomes. MDPI+1

2. Advanced radiotherapy planning (IMRT/protons as appropriate)
   Goal: focus radiation on the tumor and spare healthy brain. Modern guidelines for IDH-mutant grade 3 recommend ~59.4 Gy/33 fractions with careful target margins and organ-at-risk protection. The Green Journal+1

3. Neuro-rehabilitation (PT/OT/speech-language therapy)
   Goal: regain strength, balance, language, and daily-living skills after surgery or radiation. Rehab is a core part of multimodality glioma care to preserve function and independence. PMC

4. Cognitive rehabilitation
   Goal: train memory, attention, and executive skills affected by tumor or treatment. Programs use structured exercises and compensatory strategies integrated with daily tasks. PMC

5. Early palliative care and symptom management
   Goal: control headaches, fatigue, mood changes, and planning needs from diagnosis onward—palliative care is in addition to anti-tumor treatment and improves quality of life. PMC

6. Seizure-safety education (no routine preventive AEDs without seizures)
   Goal: reduce harm from seizures and use meds only when needed. SNO/EANO guidance: don’t start antiepileptics in patients with no prior seizure; if seizures occur, levetiracetam is commonly chosen. PubMed+1

7. Exercise as tolerated
   Goal: maintain strength, mood, and energy during/after treatment; cancer guidelines support regular, individualized physical activity when safe. ASTRO

8. Nutrition counseling
   Goal: keep weight and protein intake adequate; follow general oncology nutrition (there’s no proven anti-glioma “miracle diet”). Evidence-based advice favors balanced meals and food-safety during periods of low immunity. Cancer.gov

9. Sleep hygiene & fatigue strategies
   Goal: manage insomnia and daytime tiredness with consistent routines, light exposure, and activity scheduling; address pain/anxiety that worsen sleep. PMC

10. Psychological support (CBT, counseling, peer groups)
    Goal: reduce anxiety/depression and improve coping for patients and families, integrated with medical care. PMC

11. Occupational/vocational support
    Goal: plan safe return to work/school and adapt tasks, including driving and workplace accommodations. PMC

12. Speech-language therapy (aphasia/apraxia)
    Goal: rebuild language output/comprehension and communication strategies after tumor or treatment near eloquent cortex. PMC

13. Vision & balance therapy
    Goal: address visual field loss or vestibular issues that affect reading, mobility, and safety. PMC

14. Headache non-drug measures
    Goal: hydration, rest, dark/quiet room, and identifying triggers alongside medical care for intracranial-pressure-related headaches. American Cancer Society

15. Falls prevention & home safety review
    Goal: reduce injury risk from weakness or seizures with assistive devices and environment changes. PMC

16. Smoking and alcohol moderation counseling
    Goal: support overall health and treatment tolerance; general cancer guidance recommends cessation and moderation. Cancer.gov

17. Clinical-trial literacy and navigation
    Goal: understand and consider research options (e.g., vaccines, targeted or cell therapies) when appropriate. Cancer.gov

18. Caregiver education & respite resources
    Goal: train caregivers for safe transfers, medication timing, and recognizing emergencies; reduce burnout. PMC

19. Advance-care planning
    Goal: document preferences early, so future care matches the patient’s goals and values. PMC

20. Food-safety practices during chemo/low counts
    Goal: prevent infections by avoiding unpasteurized dairy/juices and raw sprouts; practice careful handling and cooking. Cancer.gov

---

Drug treatments

Core anti-tumor therapy

1. Temozolomide (TMZ) – oral alkylator
   Used mainly after radiotherapy for IDH-mutant grade 3 based on CATNON; typical adjuvant course is 12 cycles (day 1–5 each 28-day cycle). Purpose: kill tumor cells; benefit strongest in IDH-mutant/1p19q-non-codeleted grade 3. Common side effects: low blood counts, fatigue, nausea; monitor counts and infection risk. PMC+1

2. Radiotherapy – not a drug, but the other “backbone”
   About 59.4 Gy in 33 fractions for grade 3; planning and dose per ESTRO-EANO/American Radium Society guidance. Purpose: local control. Side effects: fatigue, hair loss, skin/scalp inflammation; late effects vary by brain region. The Green Journal+1

3. PCV (Procarbazine, CCNU/Lomustine, Vincristine)
   Sometimes used in select grade 3 settings (more standard for 1p/19q-codeleted oligodendroglioma). Purpose: cytotoxic chemotherapy; dosing is regimen-based; side effects: myelosuppression, neuropathy (vincristine), nausea. PMC

Salvage/recurrence & adjuncts (evidence varies)

4. Lomustine (CCNU)
   Common option at first progression (especially when prior TMZ used). Purpose: cytotoxic alkylator; watch for thrombocytopenia. Evidence base in recurrent HGG uses lomustine as the standard comparator. BioMed Central

5. Bevacizumab (anti-VEGF)
   May reduce edema and improve symptoms; improves progression-free survival in high-grade gliomas but not overall survival; consider in symptomatic recurrence or steroid-sparing. Side effects: hypertension, bleeding, clotting, wound-healing delays. New England Journal of Medicine+1

6. Carmustine (BCNU) wafers (surgically implanted)
   Local chemotherapy at resection; used selectively in some centers; risks include wound and healing issues. ASC Publications

Supportive & complication-focused drugs

7. Dexamethasone (steroid)
   Reduces brain swelling and headache but should be used at the lowest effective dose and tapered to limit side effects (sleep/mood changes, glucose rise, infection). ASC Publications

8. Levetiracetam (anti-seizure)
   First-line if seizures occur; not for routine prevention without a seizure history per SNO/EANO. Side effects: somnolence, mood changes. PubMed

9. Ondansetron (anti-nausea)
   Standard for chemo-induced nausea; given before TMZ doses per antiemetic guidelines. ASC Publications

10. TMP-SMX (Pneumocystis prophylaxis)
    Consider during combined chemoradiation or profound lymphopenia to prevent PJP pneumonia; dosing is typically 3x/week or daily per local protocols. Oxford Academic

11. Proton-pump inhibitor (e.g., omeprazole)
    Protects stomach lining during steroid use or when at GI-bleed risk; weigh long-term risks/benefits. ASC Publications

12. Anticoagulation for VTE (LMWH or DOAC)
    Cancer and brain tumors carry clot risk; decisions are individualized to balance bleed risk. Cancer.gov

13. G-CSF (if severe neutropenia)
    Shortens duration of low neutrophils from chemo; reduces infection risk. Cancer.gov

14. Pain medicines (stepwise from acetaminophen to opioids)
    Treats tumor-/treatment-related pain using oncology pain principles and bowel regimens if opioids are used. Cancer.gov

15. Psychotropics (SSRIs/anxiolytics) when needed
    Manage anxiety/depression/insomnia within an integrated care plan. PMC

Targeted/novel context (not standard for grade 3 AA, but relevant landscape)

16. Vorasidenib (IDH1/2 inhibitor)
    Approved for grade 2 IDH-mutant glioma after surgery (INDIGO trial improved PFS); not yet standard for grade 3 astrocytoma but shows the direction of IDH-targeting. PMC

17. Ivosidenib (IDH1 inhibitor)
    Studied in IDH-mutant gliomas; role in grade 3 remains investigational. PMC

18. Regorafenib
    Active in recurrent GBM vs lomustine in one trial; application to IDH-mutant grade 3 is uncertain and off-label. PubMed

19. Re-irradiation (not a drug; included for completeness)
    Used selectively at recurrence; evidence is limited and patient-specific. BioMed Central

20. Clinical-trial agents (vaccines, oncolytic viruses, CAR-T)
    Access via trials; see “immune/regenerative” section below. Cancer.gov

---

Dietary molecular supplements

Important note: No dietary supplement has proven to treat astrocytoma. Use only with your oncology team to avoid interactions.

1. Omega-3 (EPA/DHA)
   Function: may help maintain weight and reduce inflammation in cancer cachexia; typical studied intakes ≥1.5 g/day combined EPA+DHA. Mechanism: anti-inflammatory lipid mediators. Evidence: mixed but supportive in some trials/meta-analyses for weight/QoL. BioMed Central+1

2. Vitamin D (correct deficiency)
   Function: bone/immune health; check levels and replace if low. Evidence in glioma is observational; use standard deficiency dosing per clinician guidance. Cancer.gov

3. Melatonin (sleep aid; investigational adjunct)
   Function: sleep regulation; lab/early clinical data explore synergy with RT/TMZ, but clinical benefit in brain tumors remains inconclusive; discuss risks/benefits. PMC+1

4. Probiotics (during antibiotics/chemo-related GI upset)
   Function: support gut flora; choose evidence-based strains and avoid if severely immunocompromised unless advised. Cancer.gov

5. Ginger (anti-nausea adjunct)
   Function: modest benefit for chemo-related nausea in some settings; use standardized products; watch interactions. ASC Publications

6. Protein supplements
   Function: help meet protein targets when appetite is poor; choose safe, pasteurized products. Cancer.gov

7. Multivitamin (RDA-level)
   Function: fills minor gaps; avoid high-dose antioxidants during radiation/chemo unless approved. Cancer.gov

8. Electrolyte solutions
   Function: maintain hydration during nausea/diarrhea; follow oncology team’s advice. Cancer.gov

9. Fiber (as tolerated)
   Function: bowel regularity; adjust with diarrhea/constipation from meds. Cancer.gov

10. Calcium (if low intake and on steroids)
    Function: bone protection during steroid use, usually with vitamin D; dose individualized. ASC Publications

---

Immunity-/regenerative-/stem-cell–related drugs

These are not standard of care for grade 3 astrocytoma; access is primarily via clinical trials.

1. CAR-T cells (e.g., IL-13Rα2-targeted)
   Engineered T-cells infused into the brain/spine fluid; early-phase studies show feasibility and occasional responses, but durability varies; ongoing trials are refining targets and delivery. Nature+1

2. Oncolytic viruses (e.g., DNX-2401/Delta-24-RGD)
   Viruses injected into tumor cavities may lyse cancer cells and spark immune responses; early trials show activity signals; combinations with checkpoint blockade are under study. ASC Publications+1

3. Dendritic-cell vaccines (e.g., DCVax-L in GBM)
   Personalized vaccines aim to train immunity against tumor antigens; mixed evidence and mainly studied in glioblastoma; clinical benefit for grade 3 remains uncertain. Cancer.gov

4. Checkpoint inhibitors (nivolumab/pembrolizumab)
   Have not shown overall-survival benefit in unselected high-grade glioma; niche roles (e.g., hypermutated/MMR-deficient) are being explored. ASC Publications

5. IDH-targeted therapies (vorasidenib/ivosidenib)
   Metabolic targeting of IDH-mutant gliomas; vorasidenib improved PFS in grade 2; higher-grade roles remain under investigation. PMC

6. Stem-cell–based delivery platforms
   Neural stem cells can carry anti-cancer payloads (e.g., oncolytics/cytokines) to infiltrative tumor; early research only. PMC

---

Surgeries

1. Craniotomy with maximal-safe resection (often with awake mapping)
   Procedure removes visible tumor while testing speech/motor live to avoid harm; more extensive resection links to better outcomes. MDPI+1

2. Stereotactic biopsy
   Minimally invasive sampling when a lesion can’t be safely resected or to obtain molecular diagnosis guiding therapy. Cancer.gov

3. Re-resection at recurrence
   Selected patients may benefit from another surgery to reduce mass effect, obtain tissue for trials, and relieve symptoms. SpringerLink

4. Laser interstitial thermal therapy (LITT)
   MRI-guided laser ablation for deep/eloquent or recurrent tumors when open surgery is risky; growing but still evolving evidence base. PMC

5. CSF shunt or endoscopic third ventriculostomy
   Placed if the tumor or swelling blocks CSF flow and causes hydrocephalus; relieves pressure and symptoms like headache and nausea. Cancer.gov

---

Preventions

There’s no proven way to prevent astrocytoma. Focus on reducing general cancer risks and treatment complications:

1. Avoid unnecessary ionizing radiation exposure; use medical imaging judiciously. Cancer.gov

2. Use helmets/seatbelts to reduce traumatic brain injury (which can complicate care). Cancer.gov

3. Don’t smoke; limit alcohol. Cancer.gov

4. Keep vaccinations current (as advised by oncology team). Cancer.gov

5. Practice food safety during chemo/radiation. Cancer.gov

6. Exercise regularly as tolerated. ASTRO

7. Maintain a healthy weight and protein intake. Cancer.gov

8. Control blood pressure, diabetes, and cholesterol. Cancer.gov

9. Sun and bone health (vitamin D if deficient), especially with steroids. ASC Publications

10. Attend all follow-ups and MRIs for early detection of recurrence. Cancer.gov

---

When to see doctors (red flags)

Seek urgent help for new or worsening headaches, repeated vomiting, new seizures, sudden weakness, speech or vision changes, severe confusion/drowsiness, or any symptom that rapidly progresses. These can signal swelling, bleeding, hydrocephalus, or seizure risk and need immediate evaluation. American Cancer Society+1

---

What to eat” and “what to avoid

• Eat: small frequent meals with protein (eggs, fish, beans, dairy/yogurt), whole grains, fruits/vegetables you tolerate, and healthy fats (olive oil, nuts, omega-3–rich fish). Purpose: maintain weight and strength during treatment. Cancer.gov

• Avoid (especially when counts are low): unpasteurized milk/cheese/juice, raw or undercooked eggs/meats/fish, raw sprouts; be careful with salad bars and deli meats unless heated. Purpose: reduce infection risk. Cancer.gov

• Hydrate regularly; use oral rehydration solutions during vomiting/diarrhea. Cancer.gov

• There’s no proven anti-glioma diet (e.g., ketogenic) outside clinical trials; discuss any restrictive diet with your team to avoid malnutrition. PMC

---

Frequently asked questions

1. Is “anaplastic astrocytoma” the same as before?
   Today it’s usually called astrocytoma, IDH-mutant (grade 3); the name reflects biology and guides therapy. PMC

2. What’s the standard treatment?
   Maximal-safe surgery → RT ~59.4 Gy → adjuvant temozolomide (12 cycles) where appropriate. The Green Journal+1

3. Why is adjuvant temozolomide emphasized?
   CATNON showed survival benefit from adjuvant TMZ in 1p/19q-non-codeleted grade 3 tumors; concurrent TMZ did not add clear benefit. PMC

4. Do I need anti-seizure medicine before any seizure?
   No. Routine prophylaxis isn’t recommended; start if you have a seizure. PubMed

5. Are steroids safe long term?
   They help swelling but have many side effects; use the lowest dose for the shortest time. ASC Publications

6. What about bevacizumab?
   It can reduce swelling and improve symptoms and PFS in recurrent disease, but it doesn’t improve overall survival. New England Journal of Medicine

7. Is LITT the same as surgery?
   LITT is a minimally invasive laser ablation option for select deep/eloquent or recurrent tumors; evidence is evolving. PMC

8. Do special diets cure brain tumors?
   No. Use balanced nutrition and food-safety; consider trials before restrictive diets. Cancer.gov

9. Are IDH-targeted pills available?
   Vorasidenib is approved for grade 2 IDH-mutant gliomas after surgery; higher-grade use is investigational. PMC

10. Can immunotherapy (like in other cancers) cure this?
    Checkpoint inhibitors haven’t improved overall survival in unselected high-grade glioma; trials continue. ASC Publications

11. What follow-up do I need?
    Regular MRI and clinic visits; timing depends on treatment phase and symptoms. Cancer.gov

12. Are clinical trials important?
    Yes—many advances (vaccines, CAR-T, oncolytic viruses, targeted drugs) are only available in trials. Cancer.gov

13. What side effects should I report quickly?
    Fever, bleeding, severe headache, new seizures, confusion, chest pain, shortness of breath, or sudden weakness. Cancer.gov

14. Will I be able to work or drive?
    Often, with accommodations and seizure control; discuss legal and safety rules locally. PMC

15. How do I support my memory and speech?
    Structured cognitive and speech-language therapy + daily practice helps. PMC

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 16, 2025.